Chongqing Precision Biotech Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Chongqing China

Primary Industry

Biotechnology

About

Based in Chongqing, China, and established in 2016, Chongqing Precision Biotech Co., Ltd. is a biotechnology company that focuses on the R&D and application of gene and cell drugs for cancer. The company was co-established by Scientist professor Cheng Qian and listed company Zhifei Biologicals. It has supported drug INDs and NDA R&D center covered 18, 000 square meters. It is establishing a regional cell preparation centre (RCPC), with 10 acres. In 2018, Its product pCAR-19B receives Class I new drug clinical application acceptance. In 2019, pCAR-19B first indication approved. In 2020, pCAR-19B approved for implied clinical licences for two new indications. In 2021, Completed pCAR-19B Phase I clinical trial for adult. The company has developed more than 10 product pipelines, including leukemia, lymphoma, myeloma, kidney cancer, rectal cancer, lung cancer and breast cancer. It uses the immune cell therapy, stem cell therapy, and gene therapy. Products include pCAR-19B cell autologous transfusion preparation for acute lymphoblastic leukaemia, C-4-29 cell preparation for myeloma, renal cell carcinoma, and C-13-60 for advanced solid cancer.

Current Investors

Forward Capital, Spring Fund

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment

Website

www.precision-biotech.com

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.